# Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-2

> **NCT05836220** · PHASE3 · COMPLETED · sponsor: **Pathalys Pharma** · enrollment: 412 (actual)

## Conditions studied

- Secondary Hyperparathyroidism
- End Stage Kidney Disease

## Interventions

- **DRUG:** PLS240
- **DRUG:** Placebo
- **DRUG:** Open-Label Extension PLS240

## Key facts

- **NCT ID:** NCT05836220
- **Lead sponsor:** Pathalys Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-15
- **Primary completion:** 2025-08-05
- **Final completion:** 2025-08-05
- **Target enrollment:** 412 (ACTUAL)
- **Last updated:** 2025-09-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05836220

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05836220, "Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-2". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05836220. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*